What is Proteostasis Therapeutics'(PTI) stock price?
What is Proteostasis Therapeutics' stock price today? One share of PTI stock can currently be purchased for approximately $3.01. How much money does Proteostasis Therapeutics make? Proteostasis Therapeutics has a market capitalization of $157.08 million and generates $5 million in revenue each year.
How did PTI raise $51 million in an IPO?
(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Will Proteostasis Therapeutics (PTI) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote “Outperform” if you believe PTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Component Grades
PTI Stock Summary
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
Proteostasis Therapeutics, Inc. (PTI) Company Bio
For PTI, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
How much is Proteostasis Therapeutics stock worth in 2021?
Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases.
Is Proteostasis Therapeutics Inc. stock A Buy?
The Proteostasis Therapeutics Inc. stock price gained 2.40% on the last trading day (Wednesday, 26th May 2021), rising from $13.76 to $14.09. During the day the stock fluctuated 4.63% from a day low at $13.73 to a day high of $14.37. The price has fallen in 7 of the last 10 days and is down by -5.25% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 64 thousand more shares were traded than the day before. In total, 80 thousand shares were bought and sold for approximately $1.13 million.
What is the Moody's Investors Service?
Proteostasis Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
What is the Vickers Top Buyers and Sellers report?
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of PIMCO Corporate & Income Opportunity Fund and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 13 January 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology (ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
